<?xml version="1.0" encoding="UTF-8"?>
<ref id="CIT0010">
 <label>10.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Pitisuttithum</surname>
    <given-names>P</given-names>
   </name>, 
   <name name-style="western">
    <surname>Boonnak</surname>
    <given-names>K</given-names>
   </name>, 
   <name name-style="western">
    <surname>Chamnanchanunt</surname>
    <given-names>S</given-names>
   </name>, 
   <name name-style="western">
    <surname>Puthavathana</surname>
    <given-names>P</given-names>
   </name>, 
   <name name-style="western">
    <surname>Luvira</surname>
    <given-names>V</given-names>
   </name>, 
   <name name-style="western">
    <surname>Lerdsamran</surname>
    <given-names>H</given-names>
   </name>, 
   <name name-style="western">
    <surname>Kaewkungwal</surname>
    <given-names>J</given-names>
   </name>, 
   <name name-style="western">
    <surname>Lawpoolsri</surname>
    <given-names>S</given-names>
   </name>, 
   <name name-style="western">
    <surname>Thanachartwet</surname>
    <given-names>V</given-names>
   </name>, 
   <name name-style="western">
    <surname>Silachamroon</surname>
    <given-names>U</given-names>
   </name>, et al
  </person-group>
  <article-title>Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial</article-title>. 
  <source>Lancet Infect Dis</source>. 
  <year>2017</year>;
  <volume>17</volume>:
  <fpage>833</fpage>â€“
  <lpage>42</lpage>. doi:
  <pub-id pub-id-type="doi">10.1016/S1473-3099(17)30240-2</pub-id>.
  <pub-id pub-id-type="pmid">28533093</pub-id>
 </mixed-citation>
</ref>
